Somapacitan

Drug Profile

Somapacitan

Alternative Names: Albumin-binding somatropin - Novo Nordisk; Long-acting growth hormone - Novo Nordisk; Long-acting somatropin - Novo Nordisk; NN 8640; NNC-0195-0092

Latest Information Update: 30 May 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Somatotropin deficiency

Most Recent Events

  • 16 Jun 2017 Novo Nordisk plans a phase I trial for Somatotropin deficiency in Germany (NCT03186495)
  • 01 Apr 2017 Efficacy, adverse events and immunogenicity data from the phase III REAL 2 trial in Somatotropin deficiency presented at the 99th Annual Meeting of the Endocrine Society (ENDO - 2017)
  • 03 Mar 2017 Phase-III clinical trials in Somatotropin deficiency (Treatment-experienced, Combination therapy) in Japan (SC) (NCT03075644)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top